Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TI2, TechInvestorToo who wrote (2333)	12/18/2000 5:32:18 PM
From: Biomaven	Read Replies (2) of 52153

<<IMGN>> A somewhat controversial stock given its early history. (Don't get Rick started on this one. <g>) However, there does now seem to be significant external validation (DNA and SKB) of its current approach, and the stock is looking pretty cheap. Key to the valuation issue is whether their technique is generally applicable, which would make it a "platform" technology. (Of course we still have to see it convincingly work in one area first). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next